In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta Therapeutics, which this week announced plans to restructure amid regulator concerns over at least one of its ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta ...

SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) Jun. 30, 2025 6:26 PM ET Sarepta Therapeutics, Inc. (SRPT) ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation ...

SAN DIEGO, June 26, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and ...

Medical City Dallas announced two new executives to its C-Suite last week. Dr. Steven Merta was named chief medical officer and will oversee medical services across Medical City’s Dallas ...

Here are the major C-suite changes that occurred in May, in the order they were announced. (All changes have already taken effect unless otherwise noted.) ...

Variety will present “In the C-Suite” conversations at Cannes Lions, a series of thought-provoking discussions featuring some of the most influential leaders in marketing, branding, and ...

By Connor Hart Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market.